The Potential for Misuse and Abuse of Medications in ADHD: A Review

  title={The Potential for Misuse and Abuse of Medications in ADHD: A Review},
  author={D. Clemow and D. Walker},
  journal={Postgraduate Medicine},
  pages={64 - 81}
  • D. Clemow, D. Walker
  • Published 2014
  • Medicine
  • Postgraduate Medicine
  • Abstract This article reviews the literature concerning attention-deficit/hyperactivity disorder (ADHD) medication misuse, abuse, dependence, diversion, and malingering. The review covers nonmedical use (NMU) of both stimulant (methylphenidate and amphetamine) and nonstimulant (α-adrenergic agonists and atomoxetine) prescription medications, and provides a discussion on the relevance for ADHD treatment today. The neural basis for ADHD medication mechanisms of action (increased norepinephrine… CONTINUE READING
    82 Citations

    Paper Mentions

    Misuse of Methylphenidate.
    • D. Clemow
    • Medicine
    • Current topics in behavioral neurosciences
    • 2017
    • 14
    Reviewing the role of emerging therapies in the ADHD armamentarium.
    Adverse effects of stimulant medications in children and adolescents: focus on drug abuse
    Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications
    • 5
    Atomoxetine for the Treatment of ADHD in Incarcerated Adolescents.
    • 4
    • PDF


    Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
    • S. Kollins
    • Psychology, Medicine
    • The American journal on addictions
    • 2007
    • 63
    Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    • H. Upadhyaya
    • Psychology, Medicine
    • The Journal of clinical psychiatry
    • 2007
    • 41
    Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey.
    • G. M. Bright
    • Medicine, Psychology
    • Medscape journal of medicine
    • 2008
    • 87
    Safety of stimulant treatment in attention deficit hyperactivity disorder: part II
    • R. Merkel
    • Medicine
    • Expert opinion on drug safety
    • 2010
    • 20